In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

被引:197
|
作者
Li, J
Turnidge, J
Milne, R
Nation, RL
Coulthard, K
机构
[1] Univ S Australia, Pharmaceut Res Ctr, Adelaide, SA 5001, Australia
[2] Womens & Childrens Hosp, Dept Infect Dis, Adelaide, SA, Australia
[3] Womens & Childrens Hosp, Dept Pharm, Adelaide, SA, Australia
关键词
D O I
10.1128/AAC.45.3.781-785.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were > 128 mg/liter, For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter, The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h, Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs, Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of P. aeruginosa infections in cystic fibrosis patients.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [21] Experience with nebulised colistin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa
    Lopez-Gil Otero, Maria del Mar
    Yaiza Romero-Ventosa, Elena
    Feijoo-Melendez, Debora
    Casanova-Martinez, Cristina
    Otero-Millan, Luis
    Pineiro-Corrales, Guadalupe
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (03) : 217 - 223
  • [22] In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions
    Pompilio, Arianna
    Crocetta, Valentina
    Pomponio, Stefano
    Fiscarelli, Ersilia
    Di Bonaventura, Giovanni
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 82 (04) : 318 - 325
  • [23] Colistin Action Against Planktonic Pseudomonas aeruginosa
    Paul, Amisha
    FASEB JOURNAL, 2022, 36
  • [24] Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP)
    Marumo, Kenji
    Komukai, Daisuke
    Hirose, Makoto
    Nakamura, Hisako
    Tanaka, Hironori
    Ugajin, Kazuhisa
    Nagashima, Goro
    Yoshimura, Ashio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2013, 19 (02) : 348 - 351
  • [25] Antagonism between colistin and meropenem in Pseudomonas aeruginosa isolates from lung transplant patients
    Short, G. R.
    Perry, J. D.
    Nicholson, A.
    Scheuler, S. R.
    Fisher, A. J.
    Gould, F. K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (02): : S164 - S165
  • [26] In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Christenson, JC
    Korgenski, EK
    Daly, JA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) : 899 - 901
  • [27] ACTIVITY OF CIPROFLOXACIN AND COLISTIN AGAINST PSEUDOMONAS-AERUGINOSA ISOLATES FROM NEUTROPENIC PATIENTS - A POSSIBLE APPROACH TO PROPHYLAXIS
    MANNAN, P
    KIBBLER, CC
    NOONE, P
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (06) : 953 - 954
  • [28] Resistance and Heteroresistance to Colistin in Pseudomonas aeruginosa Isolates from Wenzhou, China
    Lin, Jie
    Xu, Chunquan
    Fang, Renchi
    Cao, Jianming
    Zhang, Xiucai
    Zhao, Yajie
    Dong, Guofeng
    Sun, Yao
    Zhou, Tieli
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (10)
  • [29] Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center
    Denton, M
    Kerr, K
    Mooney, L
    Keer, V
    Rajgopal, A
    Brownlee, K
    Arundel, P
    Conway, S
    PEDIATRIC PULMONOLOGY, 2002, 34 (04) : 257 - 261
  • [30] Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections
    Wang Hengzhuang
    Green, Kent
    Pressler, Tacjana
    Skov, Marianne
    Katzenstein, Terese L.
    Wu, Xiaojie
    Hoiby, Niels
    PEDIATRIC PULMONOLOGY, 2019, 54 (05) : 575 - 580